Friday 6 November 2026 Export BBIO’s income statement to Excel — free account

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.

Revenue: +192.6%
EPS: +55.8%
Free cash flow: +60.5%
Total debt: +4.21%

Quarter to September 2026, against a year earlier

74.39 0.12 +0.16%

Follow BBIO

Alert me

Market cap: $14.5B
P/E: 0.0×
Fwd P/E: −27.5×
Dividend yield: —
F-score: 3/9
Altman Z: −3.45
Beneish M: 8.17
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

BridgeBio Pharma, Inc. (BBIO) revenue by segment, product and region

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Net product revenue	362 72.17%	3 1.30%	0 0.00%	2 2.00%	4 5.44%	0 0.00%	—
License and services revenue	128 25.56%	219 98.62%	9 100.00%	76 98.00%	66 94.56%	8 100.00%	41 100.00%
Royalty revenue	11 2.27%	0 0.08%	0 0.00%	—	—	—	—
Revenue	502	222	9	78	70	8	41

Gross profit by product or service $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Net product revenue	‡	‡	‡	‡	‡	‡	‡
Cost of license, services, and royalty revenue	‡	‡	‡	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022
Reportable Segment	502 100.00%	222 100.00%	9 100.00%	78 100.00%
Revenue	502	222	9	78

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022
Reportable Segment	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡
Operating income	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡
	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.